The present invention provides methods of inducing anti-glatiramer acetate specific antibodies in a human subject afflicted with multiple sclerosis, comprising administration to the human subject of three subcutaneous injections of a 40 mg/ml dose of glatiramer acetate per week for at least 12 months, such that the level of anti-GA specific antibodies in the blood or serum of the human subject i) increases for up to about 6 months after an initial 40 mg/ml dose of glatiramer acetate of the administration is administered to the human subject； ii) increases at a greater rate during the first month after the initial 40 mg/ml dose of glatiramer acetate compared to the rate of increase after the first month to the third month after the initial 40 mg/ml dose of glatiramer acetate； iii) peaks at about 3 or about 6 months or between about 3 and about 6 months after the initial 40 mg/ml dose of glatiramer acetate； and iv) is higher than baseline at least about 12 months after the initial 40 mg/ml dose of glatiramer acetate.本發明提供在罹患多發性硬化症之人類個體中誘導抗格拉替雷醋酸鹽特異性抗體之方法，其包含向該人類個體每週三次皮下注射投與40mg/ml劑量之格拉替雷醋酸鹽，持續至少12個月，使得該人類個體之血液或血清中抗GA特異性抗體之含量i)在向該人類個體投與該投藥之初始40mg/ml劑量之格拉替雷醋酸鹽之後，持續長達約6個月增加；ii)與在該初始40mg/ml劑量之格拉替雷醋酸鹽之後的第一個月至第三個月之後的增加速率相比，在該初始40mg/ml劑量之格拉替雷醋酸鹽之後的第一個月期間以更高速率增加；iii)在該初始40mg/ml劑量之格拉替雷醋酸鹽之後，在約3個月或約6個月時或在約3個月與約6個月之間達到峰值；及iv)在該初始40mg/ml劑量之格拉替雷醋酸鹽之後至少約12個月高於基線。
